GlassScriptPhysician profile
Julia B Lewis
NPI 1992897326
$87,419.09
in general payments reported to CMS, 2019-2025
13 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2022: $19.69 · 2023: $11K · 2024: $26K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Travel and Lodging: $3,171 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,502 · Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,087.50 |
| Travel and Lodging | $3,171.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,502.10 |
| Food and Beverage | $675.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $20,104.54 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $13,753.07 | 2024 | |
| Travere Therapeutics, INC. | $13,223.48 | 2025 | |
| Sanofi US Services INC. | $12,807.50 | 2019 | |
| Csl Behring | $10,197.59 | 2019-2024 | |
| Novo Nordisk INC | $9,699.92 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $5,575.00 | 2025 | |
| Ardelyx, INC. | $940.00 | 2023 | |
| Biogen, INC. | $750.00 | 2025 | |
| Baxter Healthcare | $215.85 | 2019 | |
| Calliditas Therapeutics US INC. | $132.45 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.